Gastroesophageal reflux disease (GERD) and Barrett's esophagus (BE), which are exceptionally common disorders in adult Americans, are strong risk factors for esophageal adenocarcinoma. The frequency of BE- associated adenocarcinoma has increased more than six-fold in the past few decades, and the development of chemopreventive therapies for this lethal tumor has been hampered by limited understanding of the molecular events underlying the pathogenesis and neoplastic progression of BE. We have preliminary data showing that Barrett's epithelial cells are more resistant to apoptosis induced by deoxycholic acid (DCA), a hydrophobic bile acid found in refluxed gastric juice, than the squamous cells that normally line the esophagus. Such apoptotic resistance might underlie the pathogenesis and persistence of Barrett's metaplasia, as esophageal squamous cells that succumb to bile acid-induced apoptosis are replaced by apoptosis-resistant Barrett's cells. Hydrophobic bile acids like DCA also have been shown to cause DNA damage, and extensive DNA damage normally triggers apoptosis. However, we have preliminary data from in vitro and in vivo studies showing that Barrett's cells respond to bile acid-induced DNA damage by activating anti-apoptotic survival pathways. This could facilitate the neoplastic progression of Barrett's metaplasia by allowing the survival of cells that have sustained cancer-promoting mutations. Moreover, our preliminary studies suggest that esophageal squamous cells from patients with BE may be more susceptible to apoptosis induced by DNA damage than esophageal squamous cells from GERD patients without BE. This predisposition of esophageal squamous cells to succumb to apoptosis also may contribute to the development of BE. Our preliminary data suggest that the NF- ?B pathway plays a key role in the apoptotic resistance of Barrett's metaplasia. We also have preliminary data showing that ursodeoxycholic acid (UDCA), a hydrophilic bile acid, does not induce genotoxic damage in Barrett's cells in vitro or in vivo, and even protects against the DNA damage caused by DCA exposure. These findings suggest a potential chemopreventive role for UDCA. Recently, we have used telomerase technology to generate immortal, but benign (non-transformed), Barrett's cell lines and esophageal squamous cell lines from GERD patients with and without BE. We propose to use these cell lines as well as tissue specimens to explore the molecular pathways activated by bile-acid reflux that regulate apoptosis, and the role of those pathways in the development and neoplastic progression of BE. We hypothesize that bile acids influence apoptosis in esophageal cells through effects on the NF-?B pathway.
The aims of this study are to delineate the effects of bile acids on DNA damage, on the NF-?B pathway, and on apoptosis in normal esophageal squamous and metaplastic Barrett's cells in vitro and in patients in vivo, to disrupt the key NF-?B proteins and determine the effects of those disruptions on bile-acid mediated apoptosis in vitro, and to determine whether UDCA can protect against the effects of the more toxic bile acids on DNA injury and apoptosis in vitro.

Public Health Relevance

The relevance to public health is the identification of specific molecular markers that can be used to select a subset of our many patients with gastroesophageal reflux disease who might benefit from aggressive anti- reflux therapies to prevent the development of Barrett's esophagus as well as to select a subgroup of patients with Barrett's esophagus who would benefit most from interventions to prevent esophageal adenocarcinoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA134571-04
Application #
8209170
Study Section
Special Emphasis Panel (ZRG1-DIG-F (02))
Program Officer
Yassin, Rihab R,
Project Start
2009-04-01
Project End
2014-01-31
Budget Start
2012-02-01
Budget End
2013-01-31
Support Year
4
Fiscal Year
2012
Total Cost
$253,607
Indirect Cost
$52,332
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Peng, Sui; Huo, Xiaofang; Rezaei, Davood et al. (2014) In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. Am J Physiol Gastrointest Liver Physiol 307:G129-39
Wang, David H; Tiwari, Anjana; Kim, Monica E et al. (2014) Hedgehog signaling regulates FOXA2 in esophageal embryogenesis and Barrett's metaplasia. J Clin Invest 124:3767-80
Zhang, Qiuyang; Yu, Chunhua; Peng, Sui et al. (2014) Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway. Gastroenterology 146:461-72.e6
Park, Jason Y; Zhang, Xi; Nguyen, Nathalie et al. (2014) Proton pump inhibitors decrease eotaxin-3 expression in the proximal esophagus of children with esophageal eosinophilia. PLoS One 9:e101391
Huo, Xiaofang; Zhang, Xi; Yu, Chunhua et al. (2014) In oesophageal squamous cells exposed to acidic bile salt medium, omeprazole inhibits IL-8 expression through effects on nuclear factor-*B and activator protein-1. Gut 63:1042-52
Cheng, Edaire; Souza, Rhonda F; Spechler, Stuart Jon (2014) Eosinophilic esophagitis: interactions with gastroesophageal reflux disease. Gastroenterol Clin North Am 43:243-56
Cheng, Edaire; Zhang, Xi; Huo, Xiaofang et al. (2013) Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut 62:824-32
Xie, Bingru; Wang, David H; Spechler, Stuart Jon (2012) Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci 57:1122-9
Dunbar, Kerry B; Spechler, Stuart Jon (2012) The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus: a systematic review. Am J Gastroenterol 107:850-62; quiz 863
American Gastroenterological Association; Spechler, Stuart J; Sharma, Prateek et al. (2011) American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 140:1084-91

Showing the most recent 10 out of 27 publications